MWMitchell D. Wolf, MD
DexteraAI was founded by Mitchell D. Wolf, MD, a vitreoretinal surgeon with more than three decades of experience performing and teaching retinal microsurgery. He earned his B.S. and M.D. from the University of Michigan, then completed his ophthalmology residency at the University of Iowa and a vitreoretinal surgery fellowship at the Medical College of Wisconsin.
The company grew from a clinical observation: in complex subretinal therapeutic trials, small differences in surgical execution may influence procedural success, safety, and interpretation of outcomes, yet those differences are rarely quantified.
Dr. Wolf founded DexteraAI to develop objective, video-derived measures of microsurgical technical performance, beginning with subretinal gene and cell therapy delivery.
MWMartin D. Wolf
Marty brings business development, M&A, company-building, and strategic transaction experience to DexteraAI.
He is also the founder and chairman of martinwolf, a leading mid-market IT M&A Investment Bank he established in 1997. Under his leadership, the firm has helped create ~$10 billion in value across ~300 transactions. He continues to guide martinwolf's largest and most complex engagements.
Marty is a graduate of the Ross School of Business at the University of Michigan and a FINRA-registered broker.
Let's talk
If your subretinal therapy program depends on precise, reproducible surgical delivery, DexteraAI can help you measure what is currently difficult to see.